ArticleEMBO molecular medicine2024
Novel immunotherapeutics against LGR5 to target multiple cancer types.
Erratum issuedAbstract read
In one paragraph
Article in EMBO molecular medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 14 papers.
0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- LGR5: from stem cell marker to therapeutic target.Trends in cancer · 2026Review
- GPCRs in CAR-T Cell Immunotherapy: Expanding the Target Landscape and Enhancing Therapeutic Efficacy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Targeting tumor-associated G-protein coupled receptors: beyond single-axis inhibition toward multidimensional regulation.Cellular oncology (Dordrecht, Netherlands) · 2026Review
- Immuno-cytotoxic convergence: integrating antibody‒drug conjugates and immunofusion proteins to overcome resistance in gastrointestinal cancers.Journal of hematology & oncology · 2026Review
- Low LAMA2 expression may affect drug resistance and prognosis in ovarian cancer via positive LGR5 coexpression.Translational cancer research · 2026Article
- Cancer stem cell-driven drug resistance in colorectal carcinoma: molecular aspects and therapeutic potentials.Molecular cancer · 2026Review
- Next-generation CAR-T engineering for colorectal cancer: integrating targets, tumor microenvironment barriers, and emerging strategies.Frontiers in immunology · 2026Review
- Engineering CAR T NK and NKT cell therapies to target cancer stem cells and overcome stem like resistance.Discover oncology · 2025Review
- Cetuximab increases LGR5 expression and augments LGR5-targeting antibody-drug conjugate efficacy in patient-derived colorectal cancer models.Cell reports. Medicine · 2025Article
- Cetuximab increases LGR5 expression and augments LGR5-targeting antibody-drug conjugate efficacy in patient-derived colorectal cancer models.bioRxiv : the preprint server for biology · 2025Article
- Review
- Review
- Colorectal cancer stem cells crosstalk in tumor immune microenvironment and targeted therapeutic strategies.Frontiers in immunology · 2025Review
- Insights from the bottom-up development of LGR5-targeting immunotherapeutics.Immunotherapy advances · 2025Review
Corrections and comments
- Erratum issued
Authors and funding
30 authors.
Hung-Chang Chen *University of Cambridge, Cancer Research UK Cambridge Institute, Robinson Way, Cambridge, CB2 0RE, UK.
Nico Mueller *University of Cambridge, Cancer Research UK Cambridge Institute, Robinson Way, Cambridge, CB2 0RE, UK.
Katherine StottUniversity of Cambridge, Department of Biochemistry, Tennis Court Road, Cambridge, CB2 1QW, UK.ORCID http://orcid.org/0000-0002-4014-1188
Chrysa KapeniUniversity of Cambridge, Cancer Research UK Cambridge Institute, Robinson Way, Cambridge, CB2 0RE, UK.
Eilidh RiversUniversity of Cambridge, Department of Biochemistry, Tennis Court Road, Cambridge, CB2 1QW, UK.
Carolin M SauerUniversity of Cambridge, Cancer Research UK Cambridge Institute, Robinson Way, Cambridge, CB2 0RE, UK.ORCID http://orcid.org/0000-0003-2168-6630
Flavio BekeUniversity of Cambridge, Cancer Research UK Cambridge Institute, Robinson Way, Cambridge, CB2 0RE, UK.ORCID http://orcid.org/0000-0002-2294-0306
Stephen J WalshUniversity of Cambridge, Yusuf Hamied Department of Chemistry, Lensfield Road, Cambridge, CB2 1EW, UK.
Nicola AshmanUniversity of Cambridge, Yusuf Hamied Department of Chemistry, Lensfield Road, Cambridge, CB2 1EW, UK.
Louise O'BrienUniversity of Cambridge, Cancer Research UK Cambridge Institute, Robinson Way, Cambridge, CB2 0RE, UK.
Amir Rafati FardUniversity of Cambridge, Department of Biochemistry, Tennis Court Road, Cambridge, CB2 1QW, UK.ORCID http://orcid.org/0000-0003-1804-2586
Arman GhodsiniaUniversity of Cambridge, Department of Biochemistry, Tennis Court Road, Cambridge, CB2 1QW, UK.
Changtai LiUniversity of Cambridge, Department of Biochemistry, Tennis Court Road, Cambridge, CB2 1QW, UK.
Fadwa JoudUniversity of Cambridge, Cancer Research UK Cambridge Institute, Robinson Way, Cambridge, CB2 0RE, UK.
Olivier GigerUniversity of Cambridge, Department of Pathology, Tennis Court Road, Cambridge, CB2 1QP, UK.
Inti ZlobecInstitute of Pathology, University of Bern, Murtenstrasse 31, CH-3008, Bern, Switzerland.
Ioana OlanUniversity of Cambridge, Cancer Research UK Cambridge Institute, Robinson Way, Cambridge, CB2 0RE, UK.
Sarah J AitkenUniversity of Cambridge, MRC Toxicology Unit, Tennis Court Road, Cambridge, CB2 1QR, UK.ORCID http://orcid.org/0000-0002-1897-4140
Matthew HoareUniversity of Cambridge, Cancer Research UK Cambridge Institute, Robinson Way, Cambridge, CB2 0RE, UK.ORCID http://orcid.org/0000-0001-5990-9604
Richard MairUniversity of Cambridge, Cancer Research UK Cambridge Institute, Robinson Way, Cambridge, CB2 0RE, UK.ORCID http://orcid.org/0000-0001-8235-5689
Eva SerraoUniversity of Cambridge, Cancer Research UK Cambridge Institute, Robinson Way, Cambridge, CB2 0RE, UK.
James D BrentonUniversity of Cambridge, Cancer Research UK Cambridge Institute, Robinson Way, Cambridge, CB2 0RE, UK.ORCID http://orcid.org/0000-0002-5738-6683
Alicia Garcia-GimenezUniversity of Cambridge, Department of Haematology, Puddicombe Way, Cambridge, CB2 0AW, UK.
Simon E RichardsonUniversity of Cambridge, Department of Haematology, Puddicombe Way, Cambridge, CB2 0AW, UK.
Brian HuntlyUniversity of Cambridge, Department of Haematology, Puddicombe Way, Cambridge, CB2 0AW, UK.ORCID http://orcid.org/0000-0003-0312-161X
David R SpringUniversity of Cambridge, Yusuf Hamied Department of Chemistry, Lensfield Road, Cambridge, CB2 1EW, UK.ORCID http://orcid.org/0000-0001-7355-2824
Mikkel-Ole SkjoedtRigshospitalet-University Hospital Copenhagen, Blegdamsvej 9, 2100, Copenhagen, Denmark.ORCID http://orcid.org/0000-0003-1306-6482
Karsten SkjødtUniversity of Southern Denmark Campusvej 55, Odense M, DK-5230, Denmark.
Marc de la RocheUniversity of Cambridge, Department of Biochemistry, Tennis Court Road, Cambridge, CB2 1QW, UK. mad58@cam.ac.uk.ORCID http://orcid.org/0000-0002-3757-082X
Maike de la RocheUniversity of Cambridge, Cancer Research UK Cambridge Institute, Robinson Way, Cambridge, CB2 0RE, UK. maike.delaroche@cruk.cam.ac.uk.ORCID http://orcid.org/0000-0002-0558-4119
Funding
Cancer Research UK 22257Cancer Research UK (CRUK) A22257Cancer Research UK (CRUK) C18873/A26813Cancer Research UK (CRUK) C52489/A19924Cancer Research UK (CRUK) C63389/A30462Cancer Research UK (CRUK) C67279/A27957Cancer Research UK (CRUK) RCCCSF-May23/100001Pathological Society of Great Britain and Ireland 3903171UKRI | Medical Research Council (MRC) RG94521Wellcome TrustWellcome Trust (WT) 107609/Z/15/ZWellcome Trust (WT) 203151/Z/16/ZWellcome Trust (WT) 222062/Z/20/ZWellcome Trust (WT) 227432/Z/23/Z
Abstract
We have developed and validated a highly specific, versatile antibody to the extracellular domain of human LGR5 (α-LGR5). α-LGR5 detects LGR5 overexpression in >90% of colorectal cancer (CRC), hepatocellular carcinoma (HCC) and pre-B-ALL tumour cells and was used to generate an Antibody-Drug Conjugate (α-LGR5-ADC), Bispecific T-cell Engager (α-LGR5-BiTE) and Chimeric Antigen Receptor (α-LGR5-CAR). α-LGR5-ADC was the most effective modality for targeting LGR5
Indexed as
Receptors, G-Protein-CoupledAnimalsCell Line, TumorDisease Models, AnimalHumansImmunoconjugatesImmunotherapyMiceNeoplasmsImmunoconjugatesLGR5 protein, humanReceptors, G-Protein-CoupledADCBiTECancer ImmunotherapeuticsCARLGR5
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.